Cytogenetics & FISH in Leukemia
Essential for risk classification
Understand chromosomal abnormalities in leukemia and how cytogenetics and FISH testing guide treatment selection
What are Cytogenetics and FISH?
Cytogenetics and FISH (Fluorescence In Situ Hybridization) are tests that identify chromosomal abnormalities in leukemia cells. These abnormalities are foundational to leukemia classification and are the single most important prognostic factor in acute myeloid leukemia (AML).
Specific chromosomal translocations predict chemotherapy response, prognosis, and guide clinical trial eligibility. All patients with newly diagnosed leukemia should have cytogenetic and FISH testing.
Major Chromosomal Abnormalities in AML
Favorable-Risk Cytogenetics
Examples: t(15;17), t(8;21), inv(16)
Associated with better prognosis and chemotherapy response. t(15;17) defines acute promyelocytic leukemia (APL) treated with arsenic/ATRA. t(8;21) and inv(16) have 70-80% 5-year survival with standard chemotherapy.
Intermediate-Risk Cytogenetics
Examples: Normal karyotype (no abnormalities)
Most common (~45% of AML). Prognosis depends on molecular markers (NPM1, FLT3-ITD, TP53). 40-50% 5-year survival with standard therapy. Molecular testing essential for risk stratification.
Adverse-Risk Cytogenetics
Examples: Complex karyotype, t(9;22), TP53 mutation
Associated with poor prognosis. <15% 5-year survival with standard chemotherapy. Requires intensive treatment approaches including allogeneic stem cell transplantation or novel targeted therapies.
Common Translocations in AML
Specific chromosomal abnormalities define AML subtypes:
- t(15;17): Acute promyelocytic leukemia (APL). Responds to arsenic trioxide + all-trans retinoic acid. Excellent prognosis (85-90% 5-year survival)
- t(8;21): RUNX1-RUNX1T1 fusion. 70-80% 5-year survival. Standard chemotherapy effective
- inv(16): CBFB-MYH11 fusion. Similar to t(8;21), good prognosis (~70% survival)
- t(9;22): BCR-ABL fusion (Philadelphia chromosome). Defines chronic myeloid leukemia (CML). Requires tyrosine kinase inhibitor therapy
- Complex karyotype: ≥3 chromosomal abnormalities. Very poor prognosis
How FISH Testing Works
FISH uses fluorescently labeled probes that bind to specific DNA sequences:
- Can detect specific translocations even when standard cytogenetics is unsuccessful
- Faster results than traditional cytogenetics (hours vs. days)
- More sensitive for detecting abnormal cells
- Can identify minimal residual disease (MRD) during treatment
Cytogenetics in Clinical Trials
Cytogenetic findings guide clinical trial eligibility and stratification:
- Favorable-risk trials: May enroll only favorable-risk cytogenetics for reduced-intensity therapy
- Adverse-risk trials: Target poor-prognosis patients with t(9;22), complex karyotype, or TP53 mutations
- APL-specific trials: Target t(15;17) exclusively
- Stratification: Most trials stratify by cytogenetic risk group
Find Matching Trials →
Frequently Asked Questions
Why is cytogenetics important for leukemia?
▼
Cytogenetics is the most important prognostic factor in leukemia because:
- Specific translocations define leukemia subtypes
- Chromosomal abnormalities predict chemotherapy response
- Cytogenetic risk groups guide treatment intensity
- Some cytogenetic subtypes require specific targeted therapies
- Risk classification affects trial eligibility
What does favorable-risk cytogenetics mean?
▼
Favorable-risk cytogenetics means your leukemia has chromosomal abnormalities associated with good prognosis:
- t(15;17): Acute promyelocytic leukemia with excellent prognosis (85-90% 5-year survival)
- t(8;21) or inv(16): Good chemotherapy response with 70-80% 5-year survival
Favorable-risk patients often respond well to standard chemotherapy and may not need intensive transplantation.
What does adverse-risk cytogenetics mean?
▼
Adverse-risk cytogenetics means your leukemia has chromosomal abnormalities associated with poor prognosis:
- Complex karyotype (≥3 abnormalities)
- t(9;22) BCR-ABL fusion
- TP53 mutations
These patients have <15% 5-year survival with standard chemotherapy alone. More aggressive treatment (transplantation or novel targeted therapies) is typically recommended.
What is the difference between cytogenetics and FISH?
▼
Both tests identify chromosomal abnormalities but use different methods:
- Cytogenetics: Examines whole chromosomes under microscope. Takes 10-14 days. Shows overall chromosome structure
- FISH: Uses fluorescent probes for specific sequences. Takes 24-48 hours. Very sensitive for specific translocations
Both are typically performed together. FISH provides faster results for specific translocations, while cytogenetics gives a complete chromosome picture.
Can normal cytogenetics have poor prognosis?
▼
Yes. Normal cytogenetics (no detectable chromosomal abnormalities) is the most common finding (~45% of AML) but prognosis depends on molecular markers:
- NPM1+ without FLT3-ITD: Favorable (60% 5-year survival)
- FLT3-ITD positive: Adverse (15-20% 5-year survival)
- TP53 mutation: Adverse (<5% 5-year survival)
For normal cytogenetics, molecular testing (NPM1, FLT3-ITD, TP53) is essential to determine prognosis.
How does cytogenetics affect clinical trial eligibility?
▼
Cytogenetics significantly affects trial eligibility:
- Some trials enroll only favorable-risk cytogenetics
- Others specifically target adverse-risk disease
- APL-specific trials require t(15;17)
- Most trials use cytogenetics as a stratification factor
Having your cytogenetic results will help identify which clinical trials are appropriate for you.